Related Experiment Video
Updated: Jul 29, 2026
04:44
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
Diffuse panbronchiolitis and rheumatoid arthritis-associated bronchiolar disease: similarities and differences
H Hayakawa1, A Sato, S Imokawa
1Department of Internal Medicine, National Sanatorium Tenryu Hospital, Hamakita.
Internal Medicine (Tokyo, Japan)
|July 25, 1998
Summary
Diffuse panbronchiolitis (DPB) and rheumatoid arthritis-associated bronchiolar disease (RA-BD) share symptoms but differ histologically and genetically. Erythromycin treatment was less effective for RA-BD, indicating they are distinct conditions.
Area of Science:
- Pulmonology
- Rheumatology
- Immunogenetics
Background:
- Diffuse panbronchiolitis (DPB) and rheumatoid arthritis-associated bronchiolar disease (RA-BD) present overlapping clinical and histological features.
- Differentiating these conditions is crucial for appropriate patient management and treatment strategies.
Purpose of the Study:
- To investigate the distinguishing characteristics between DPB and RA-BD.
- To identify key differences in clinical presentation, histology, treatment response, and genetic markers.
Main Methods:
- Comparative analysis of 25 DPB patients and 15 RA-BD patients.
- Evaluation of clinical symptoms, pulmonary function tests (PFTs), cold hemagglutinin titers, and HLA B54 frequency.
- Histological examination of lung tissue.
- Assessment of treatment response to long-term erythromycin therapy.
Main Results:
- Both groups exhibited chronic cough, dyspnea, purulent sputum, sinusitis history, decreased PaO2 and FEV1.0.
- Histologically, panbronchiolitis lesions were more prevalent in DPB (68% vs 20%), while bronchiolar obliteration occurred more proximally in RA-BD.
- Erythromycin showed less efficacy in RA-BD patients, and HLA B54 was more frequent in DPB (50.0% vs 22.2%).
Conclusions:
- DPB and RA-BD are distinct conditions despite overlapping features.
- Histopathological patterns, treatment response to erythromycin, and HLA B54 frequency serve as key differentiators.
Related Concept Videos
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
01:23Rheumatic Heart Disease I: Introduction
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
01:28Asthma I: Introduction
Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...
01:23Chronic Obstructive Pulmonary Disease II: Emphysema
Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.
01:24Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
01:19Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations
Chronic Obstructive Pulmonary Disease, or COPD, is a long-term condition marked by persistent and only partially reversible airflow limitation. It involves two overlapping conditions—chronic bronchitis and emphysema—which often co-appear but differ in dominant symptoms and underlying mechanisms.Chronic Bronchitis FeaturesChronic bronchitis presents with a persistent productive cough and thick, sometimes purulent mucus due to airway inflammation, enlarged mucus glands, and goblet cell...